Home › Companies › EWTX

Edgewise Therapeutics

Most recent annual filing: 2026-02-26

Catalyst timeline

11 trackedQuarter catalyst calendar →
  1. mavacamten competitor Ph3 start2026mavacamten competitor Ph3 start, 2026, routine
  2. EDG-7500 FDA feedback2H 2026EDG-7500 FDA feedback, 2H 2026, material
  3. sevasemten topline4Q 2026sevasemten topline, 4Q 2026, material
  4. EDG-7500 Ph3 start4Q 2026EDG-7500 Ph3 start, 4Q 2026, notable
  5. aficamten competitor sNDA filing4Q 2026aficamten competitor sNDA filing, 4Q 2026, notable
  6. EWTX corporate updateNov 5, 2026EWTX corporate update, Nov 5, 2026, routine
  7. EDG-7500 readout1H 2027EDG-7500 readout, 1H 2027, material
  8. BHB-1893 competitor Ph3 start1H 2027BHB-1893 competitor Ph3 start, 1H 2027, routine
  9. EDG-003 corporate update2027EDG-003 corporate update, 2027, routine
  10. EDG-15400 Ph2 readout2H 2027EDG-15400 Ph2 readout, 2H 2027, material
  11. aficamten competitor interim2H 2027aficamten competitor interim, 2H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Technology platforms

muscle focused drug discovery platform

Proprietary muscle-focused drug discovery platform using custom high-throughput and translatable systems measuring integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue; focused on rare neuromuscular and cardiac diseases including muscular dystrophies and cardiometabolic diseases.

Targets: sarcomere modulators, myosin

EDG-003

Cardiometabolic discovery program targeting novel cardiometabolic targets; preclinical stage; part of Edgewise's broader muscle-focused drug discovery platform

Discontinued (1)

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.